Pulmonary & nasal

As a global CDMO leader in drug-device combination products, Kindeva Drug Delivery supports pharma and biotech clients with the development and manufacturing of a full spectrum of pulmonary & nasal drug delivery products for respiratory and systemic diseases. Our expertise includes generics, new chemical entities, and reformulations, and we are leading the way in green propellants. Clinical supply for HFA-152a and HFO-1234ze is available now at our Loughborough, U.K., facility, and we will be the first CDMO to launch a commercial line for these propellants, planned for production in 2025.


Through our St. Louis facilities, we combine device manufacture, sterile fill-finish, and final assembly in one geographic location, simplifying your supply chain. From clinical to niche commercial and large-scale commercial manufacturing, Kindeva can support all your injectable needs in-house. We invented the first autoinjector and in the 60 years since this innovation, we have continued to develop and manufacture new platforms that deliver outstanding reliability and quality, as well as working with third-party platforms.

Microneedle array patches

Across small and large molecules including vaccines, peptides, proteins, and biologics, our microneedle array patch platforms could deliver broad-reaching benefits, including the potential to eliminate cold chain storage. With capabilities to produce ~14 million patches per year for commercial manufacturing and over 1 million patches for clinical trials, our capacity scales with your therapy.


From patches to pharmaceutical- and medical-grade GMP coating capabilities to tech transfers, our transdermal drug-delivery technologies impact positive health outcomes all over the globe. When you need a proven innovator with a history of launching next-generation drug-delivery systems, combine forces with Kindeva.

Combine Forces With Kindeva